Celldex Therapeutics, Inc. SEC filings CLDX
Celldex Therapeutics, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Oct 31, 2007. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 6, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | Nov 2, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 8, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 4, 2023 | Mar 31, 2023 |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 8, 2022 | Jun 30, 2022 |
| 10-Q | Quarterly report | May 5, 2022 | Mar 31, 2022 |
| 10-Q | Quarterly report | Nov 9, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 5, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 6, 2021 | Mar 31, 2021 |
| 10-Q | Quarterly report | Nov 5, 2020 | Sep 30, 2020 |
| 10-Q | Quarterly report | Aug 6, 2020 | Jun 30, 2020 |
| 10-Q | Quarterly report | May 6, 2020 | Mar 31, 2020 |
| 10-Q | Quarterly report | Nov 12, 2019 | Sep 30, 2019 |
| 10-Q | Quarterly report | Aug 7, 2019 | Jun 30, 2019 |
| 10-Q | Quarterly report | May 7, 2019 | Mar 31, 2019 |
| 10-Q | Quarterly report | Nov 7, 2018 | Sep 30, 2018 |
| 10-Q | Quarterly report | Aug 8, 2018 | Jun 30, 2018 |
| 10-Q | Quarterly report | May 10, 2018 | Mar 31, 2018 |
| 10-Q | Quarterly report | Nov 7, 2017 | Sep 30, 2017 |
| 10-Q | Quarterly report | Aug 8, 2017 | Jun 30, 2017 |
| 10-Q | Quarterly report | May 9, 2017 | Mar 31, 2017 |
| 10-Q | Quarterly report | Nov 7, 2016 | Sep 30, 2016 |
| 10-Q | Quarterly report | Aug 8, 2016 | Jun 30, 2016 |
| 10-Q | Quarterly report | May 5, 2016 | Mar 31, 2016 |
| 10-Q | Quarterly report | Nov 5, 2015 | Sep 30, 2015 |
| 10-Q | Quarterly report | Aug 10, 2015 | Jun 30, 2015 |
| 10-Q | Quarterly report | Apr 29, 2015 | Mar 31, 2015 |
| 10-Q | Quarterly report | Nov 5, 2014 | Sep 30, 2014 |
| 10-Q | Quarterly report | Aug 7, 2014 | Jun 30, 2014 |
| 10-Q | Quarterly report | May 1, 2014 | Mar 31, 2014 |
| 10-Q | Quarterly report | Nov 8, 2013 | Sep 30, 2013 |
| 10-Q | Quarterly report | Aug 6, 2013 | Jun 30, 2013 |
| 10-Q | Quarterly report | May 3, 2013 | Mar 31, 2013 |
| 10-Q | Quarterly report | Nov 2, 2012 | Sep 30, 2012 |
| 10-Q | Quarterly report | Aug 9, 2012 | Jun 30, 2012 |
| 10-Q | Quarterly report | May 4, 2012 | Mar 31, 2012 |
| 10-Q | Quarterly report | Nov 3, 2011 | Sep 30, 2011 |
| 10-Q | Quarterly report | Aug 4, 2011 | Jun 30, 2011 |
| 10-Q | Quarterly report | May 5, 2011 | Mar 31, 2011 |
| 10-Q/A | Amended quarterly report | Dec 23, 2010 | Sep 30, 2010 |
| 10-Q | Quarterly report | Nov 4, 2010 | Sep 30, 2010 |
| 10-Q | Quarterly report | Aug 5, 2010 | Jun 30, 2010 |
| 10-Q | Quarterly report | May 6, 2010 | Mar 31, 2010 |
| 10-Q | Quarterly report | Nov 6, 2009 | Sep 30, 2009 |
| 10-Q | Quarterly report | Aug 7, 2009 | Jun 30, 2009 |
| 10-Q | Quarterly report | May 8, 2009 | Mar 31, 2009 |
| 10-Q | Quarterly report | Nov 10, 2008 | Sep 30, 2008 |
| 10-Q | Quarterly report | Aug 11, 2008 | Jun 30, 2008 |
| 10-Q | Quarterly report | May 19, 2008 | Mar 31, 2008 |
| 10-Q | Quarterly report | Nov 7, 2007 | Sep 30, 2007 |
Showing 59 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CLDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hampton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 744218
- Former names
- AVANT IMMUNOTHERAPEUTICS INC (until Sep 29, 2008); T CELL SCIENCES INC (until Aug 21, 1998)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.